History
Founded in 2011, Samabriva is a biotechnology company which has developed a disruptive platform (the “RHIZOBRIVA™” platform) from plant material enabling the production of biomolecules suitable for the pharmaceutical industry, as well as the cosmetics, agrochemicals and food industries
More recently, Samabriva has built an independent business unit (the “NANOBRIVA™” platform) focused on the development of orphan drugs for the treatment of lysosomal storage disorders (« LSD »). In this business unit, the company develops proprietary lysosomal enzymes with novel and enhanced bioavailability features, taking advantage of an innovative technology compatible with all production systems (mammalian cell cultures, bacteria, etc …).
RhizoBriva™
A greentech platform gathering the advantages of both plants and bioreactor-confined processes to produce complex molecules
NanoBriva ™
An innovative platform to develop first-in-class products in the lysosomal storage disorder area
CONTACT
72 rue des Jacobins 80 000 Amiens
+33 (0) 322 092 830